Nov 11: KOSDAQ +5.62%, Three Limit-Ups, and MedPacto Has No Filing
MedPacto, Noul and Ecocap all closed at the 30% daily limit, but the support differs: press reports only for MedPacto, a change-of-largest-shareholder filing for Noul, and filings for Ecocap that are not tied to the rally.

Updated 4:38 pm KST on Nov 11, 2026, regular-session closing prices. This article covers the three stocks that closed at the 30% daily limit (MedPacto, Noul, Ecocap). All three were already at the limit at 1:30 pm and held it to the close.

Seoul — KOSDAQ, Korea's tech- and small-cap-heavy market, rose 5.62% to 705.10 and the KOSPI gained 2.6% to 5,375.36 on Nov 11, and MedPacto, Noul and Ecocap each closed at the 30% daily limit. All three finished with buy orders unfilled, but the support differs. MedPacto has no filing in the past seven days, only reports of 'technology transfer' hopes. Noul has a change-of-largest-shareholder filing. Ecocap has a share-buyback trust filing, though nothing confirms it drove today's jump.
At a glance
| Stock (code) | Close / change | Value traded | Why it rose | Nature | Evidence | Overheating | What to check next |
|---|---|---|---|---|---|---|---|
| MedPacto (235980) | 4,660 won, +29.99% | 9.4 bn won | Reports of tech-transfer talks at BIO-Europe | Expectation | Reports only | 3/4, strong | Whether the company discloses any deal |
| Noul (376930) | 2,375 won, +29.92% | 9.8 bn won | New largest shareholder (Jigu Holdings) report; filing | Expectation | Filing confirmed | 3/4, strong | Stake size and issuance details |
| Ecocap (128540) | 1,190 won, +29.91% | 13.6 bn won | Buyback trust, pledge release; link unconfirmed | Expectation | Filing (indirect) | 3/4, strong | Buyback size and period; order filings |
MedPacto (235980): reports of tech-transfer hopes, and no filing

MedPacto, a cancer drug developer, closed up 29.99% at 4,660 won. Hankyung reported the limit-up on 'global technology transfer hopes', Pharmnews said it released preclinical data on its candidate MP010 at BIO-Europe, and PRESS9 and Newdaily reported it was discussing or sounding out technology transfer. But DART, Korea's official disclosure system, shows no MedPacto filing in the past seven days, and the headlines describe 'talks' and 'soundings', not a contract. The Public also reported preparations for Korea-US clinical trials of MP010.
Three of four overheating signals are on (strong overheating): RSI 80.5, a price 39.3% above its 20-day average, and volume 8.2 times the 20-day average. The stock is 42.1% below its 52-week high and 14.8% above its 200-day line. It passes 2 of 6 fundamental checks, as it is loss-making with negative free cash flow. Sell orders were zero and buy orders stood at 178,032 shares. On the prior trading day (Nov 10) foreigners net sold 227,871 shares and individuals net bought 228,153. With a 34.3% gain over five days, this may be short-term overheating.
None of the reports says a contract was signed. To judge whether this lasts, watch whether the company confirms talks or a deal in a filing, and whether trading value holds near today's 9.4 billion won.
Reports checked (Nov 11): Hankyung, Pharmnews, PRESS9, Newdaily. Filings: none.
Noul (376930): up 89% in three days after a largest-shareholder filing

Noul closed up 29.92% at 2,375 won, after +29.96% on Nov 9 and +12.08% on Nov 10, an 89% rise in three days from the Nov 6 close of 1,255 won. According to DART, Noul filed a 'change of largest shareholder' and a 'securities issuance result (voluntary disclosure)' on Nov 9, and Financial News reported that the AI blood and cancer diagnostics company has investment holding company Jigu Holdings as its new largest shareholder and is pushing into the domestic market. We rate the filings neutral. The titles alone do not show the stake size or issuance amount.
The stock has been hit hard before. After two straight limit-ups on Oct 23 and 26 it fell to 1,255 won by Nov 6, 42% below the 2,170-won peak. Overheating signals are 3 of 4: 50.2% above the 20-day average, volume 5.0 times normal, and a 79.7% five-day gain. It is 83.6% below its 52-week high and 52.3% below its 200-day line. It passes 1 of 6 fundamental checks, and the checklist's revenue growth figure is -28.0%. Value traded of 9.8 billion won is about 40% of the 24.4 billion won market cap, which may be short-term overheating. Foreigners net sold 96,970 and 125,256 shares on Nov 9 and 10, with individuals on the other side.
To judge this, read the filings for the stake and method of the shareholder change and the number and recipient of newly issued shares. New share issuance can weigh on existing holders. Whether trading value holds next session also matters.
Filings checked (Nov 9): Change of largest shareholder, Securities issuance result (voluntary). Report: Financial News (Nov 10).
Ecocap (128540): filings exist, but none is tied to the jump

Ecocap, an auto wiring-parts maker, closed up 29.91% at 1,190 won. DART shows a Nov 6 filing on a decision to sign a treasury-share acquisition trust contract (favorable; the amount is not visible from the title), plus substantial-holding reports on Nov 6 and Nov 10. Data Investment reported that largest shareholder Kim Chang-gyu released all 2,814,259 pledged shares, and Vegan News said Choi Young-chun's stake fell 6.75 points to 3.24% (a caution item). Neither the filings nor the headlines confirm which, if any, drove the limit-up. Geumgang Ilbo asked 'why the surge?' and Jobpost wrote that wiring-parts orders are the key.
The stock rose 114.4% in five days from 555 won on Nov 4. It hit the limit on Nov 5, 6 and 9, fell 10.06% on Nov 10, and rebounded today, yet it is only 6.6% above its Oct 7 close, so it is back near its level of a month ago. It was designated a 'caution' stock on Nov 10 (Topstar News). Overheating signals are 3 of 4: 37.5% above the 20-day average, volume 9.6 times normal, and a 114.4% five-day gain. It is 23.4% below its 200-day line and 58.2% below its 52-week high. It passes 3 of 5 fundamental checks (profitable, positive free cash flow, debt), but revenue growth is -9.8%. Value traded of 13.6 billion won is about 43% of the 31.8 billion won market cap, which may be short-term overheating, and buy orders at the limit stood at 442,501 shares. On Nov 10 foreigners net sold 340,213 shares and individuals net bought 319,483.
Two things to check: the size and period of the buyback in the filing text, and whether the wiring-parts order mentioned in the press shows up in a filing. Further changes in major shareholders' stakes also matter.
Filings checked: Nov 6 Treasury-share acquisition trust decision, Nov 6 Substantial holding report (Choi), Nov 10 Substantial holding report (Kim).
FAQ
Why did they rise? MedPacto on reports of tech-transfer talks (Hankyung and others), Noul on reports of a new largest shareholder and a related filing, and Ecocap for a reason that is not directly confirmed.
Which filings back it? Noul's Nov 9 largest-shareholder change and issuance result; Ecocap's Nov 6 buyback trust decision and holding reports on Nov 6 and 10. MedPacto has none in the past seven days.
What to watch next? No confirmed schedule has been disclosed for any of the three. Watch Nov 12 trading value and new filings.
How the stocks we covered earlier did
The table shows our earlier verdict and the move from that article's close to the Nov 11 close. The two filing-based names split: Hanjin -6.1% and Mercury +6.6%. Of the four report-based names, Samik Pharm and Jin Air rose 1.9% each, while Pharmicell fell 9.3% and Daedong Metal 12.0%. Duksung (-9.7%) and Elice (+2.0%) have no recorded verdict, so they are marked unconfirmed.
| Stock | Article date | Verdict then | Move since |
|---|---|---|---|
| Hanjin | Nov 10 | Filing | -6.1% |
| Samik Pharm | Nov 10 | Reports | +1.9% |
| Jin Air | Nov 10 | Reports | +1.9% |
| Mercury | Nov 9 | Filing | +6.6% |
| Pharmicell | Nov 9 | Reports | -9.3% |
| Daedong Metal | Nov 9 | Reports | -12.0% |
| Duksung | Nov 6 | Unconfirmed | -9.7% |
| Elice | Nov 6 | Unconfirmed | +2.0% |
FAQ
Why did MedPacto stock go up?
4,660 won, +29.99%. Evidence: Reports of tech-transfer talks at BIO-Europe. What to check next: Expectation.
Why did Noul stock go up?
2,375 won, +29.92%. Evidence: New largest shareholder (Jigu Holdings) report; filing. What to check next: Expectation.
Why did Ecocap stock go up?
1,190 won, +29.91%. Evidence: Buyback trust, pledge release; link unconfirmed. What to check next: Expectation.